The key regulatory dates: April 22, 2025 Enforcement discretion ended for 503A state-licensed pharmacies compounding semaglutide May 22, 2025 Enforcement discretion ended for 503B outsourcing facilities Ongoing The FDA issued warning letters to 30 telehealth companies for making misleading claims about compounded semaglutide
Gastrointestinal side effects were the most commonly reported adverse events, were generally mild to moderate in severity, and usually occurred during the dose escalation period
This altered baseline metabolic context could modulate the host response to GLP-1 receptor agonist therapy, which has itself been associated with microbial remodeling and shifts in gut-derived signaling metabolites (81)
[Ref] Renal Common (1% to 10%): Kidney failure (chronic hemodialysis patients) [Ref] Endocrine Common (1% to 10%): Parathyroid disorder [Ref] Respiratory Very common (10% or more): Pharyngitis (27%), cough increase (18%), dyspnea (11%), rhinitis (11%) Common (1% to 10%): Bronchitis, sinusitis [Ref] Dermatologic Common (1% to 10%): Pruritus, rash [Ref] Ocular Common (1% to 10%): Amblyopia, eye disorder [Ref] Genitourinary Common (1% to 10%): Urinary tract infection [Ref] Cardiovascular Very common (10% or more): Hypertension (21%), hypotension (19%) Common (1% to 10%): Atrial fibrillation, arrhythmia, cardiovascular disorder, electrocardiogram abnormal, palpitations, tachycardia, vascular disorder [Ref] Hypersensitivity Common (1% to 10%): Allergic reaction [Ref] Psychiatric Common (1% to 10%): Depression, anxiety, drug dependence, insomnia [Ref] Immunologic Very common (10% or more): Infection (24%) [Ref] References 1
[DOI] [PubMed] [Google Scholar] (118).Kogan NM
The temporal dynamics of 5-amino-1MQ's cellular effects reveal sophisticated regulatory mechanisms that extend well beyond immediate enzyme inhibition
